Mucins lowering program

Patients with mucin originated lung disease are susceptible to mortality and morbidity. Effective treatment of mucin hyper-production in the airway of the lung is not available and there is an arising interest for researchers to develop an effective and potent agent in the treatment of mucin induced lung disease.

SpliSense’s objective is to identify Antisense Oligonucleotides (ASOs) that can modulate and lower MUC5AC and/or MUC5B expression and production in a specific manner and thus potentially reduce mucin levels in mucus, decrease mucus viscosity and accumulation in the airways, and reduce infection and inflammation.

Scroll Up Skip to content